Inhibrx Biosciences Inc. (INBX) vs Ultragenyx Pharmaceutical Inc. (RARE)
A side-by-side comparison of Inhibrx Biosciences Inc. and Ultragenyx Pharmaceutical Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
INBX
Inhibrx Biosciences Inc.
$93.41HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
RARE
Ultragenyx Pharmaceutical Inc.
$14.46HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
Total return — INBX vs RARE
growth of $100 · dividends reinvested · last 6yINBX +382.3% (+30.0%/yr)RARE -83.5% (-25.9%/yr)INBX compounded faster over this window
Log scale — wide-divergence pair
INBX RARE
INBX vs RARE: by the numbers
- •RARE is the larger company ($1.42B vs $1.37B market cap).
- •Both run net losses; RARE's is the smaller (-81.79% vs -10773.46% net margin).
Metrics side by side
Valuation
| Metric | INBX | RARE |
|---|---|---|
| P/S ratio | N/A | 1.99 |
Profitability
| Metric | INBX | RARE |
|---|---|---|
| Gross margin | -91.00% | 83.12% |
| Operating margin | -10386.54% | -73.77% |
| Net margin | -10773.46% | -81.79% |
| ROIC | -99.35% | -53.48% |
Growth (annualized)
| Metric | INBX | RARE |
|---|---|---|
| Revenue CAGR (5Y) | N/A | 14.81% |
| Total return CAGR (5Y) | 27.64% | -30.14% |
Frequently asked
- How have INBX and RARE total returns compared?
- Over the past 5 years, INBX delivered 27.64% and RARE delivered -30.14% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.